Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JRS-II HR high-risk rhabdomyosarcoma multi-agent chemotherapy study
jRCTs051180208Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, irinotecan, pirarubicin, cyclophosphamide, ifosfamide and 2 more in alveolar rhabdomyosarcoma (ARMS), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of progressive disease until 54 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
vincristineirinotecanpirarubicincyclophosphamideifosfamide
03
Conditions
alveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on jRCTs051180208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180208.